U.S. markets closed

Inozyme Pharma, Inc. (INZY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.14-0.08 (-1.53%)
At close: 04:00PM EDT
5.09 -0.05 (-0.97%)
After hours: 04:14PM EDT

Inozyme Pharma, Inc.

321 Summer Street
Suite 400
Boston, MA 02210
United States
(857) 330-4340

Full Time Employees59

Key Executives

NameTitlePayExercisedYear Born
Dr. Douglas A. Treco Ph.D.CEO & Chairman77kN/A1958
Mr. Axel Bolte M.B.A., M.Sc.Co-Founder, Senior Advisor & Director1.03MN/A1972
Mr. Sanjay S. Subramanian M.B.A., M.S.Senior VP, CFO & Principal Accounting Officer726.3kN/A1977
Dr. Demetrios Braddock M.D., Ph.D.Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board ObserverN/AN/AN/A
Dr. Matthew Winton Ph.D.Senior VP & COON/AN/A1978
Dr. Soojin Kim Ph.D.Senior VP & Chief Technical Operations OfficerN/AN/AN/A
Dr. David Thompson M.A., M.S., Ph.D.Senior VP, Chief Scientific Officer & Chief Development OfficerN/AN/AN/A
Mr. Stefan RileyDirector of Investor RelationsN/AN/AN/A
Ms. Gayle GirondaSenior VP & Chief People OfficerN/AN/AN/A
Dr. Yves Sabbagh Ph.D.Chairman of Scientific Advisory Board & Senior VPN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Corporate Governance

Inozyme Pharma, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.